Dr. Sandeep N. Athalye
Chief Development Officer
Dr. Sandeep Athalye is the Chief Development Officer at Biocon Biologics. After a stint with Biocon early in his career, Sandeep joined back the organization in 2017 and has since been responsible for Clinical Development & Operations, Pharmacovigilance & Drug Safety and Medical Affairs. He assumed his current role in 2019.
He has over 20 years of experience in Clinical Development and Medical Affairs spanning US, Europe, and Asia. Sandeep spent 12 years in the US with Schering Plough and Novartis, where he was responsible for global development of assets across several therapeutic areas. He then led the clinical development team at Biocon, before taking up a leadership role at Boehringer Ingelheim in Germany in the Biosimilars Unit. He also has experience of setting up development operations in China.
Sandeep has done a mini MBA in BioPharma Innovation at the Rutgers University, New Brunswick, US; a MS in Clinical Pharmacology at the University of Toledo, US and an MBBS in Medicine at the Bharati Vidyapeeth, India.